Here, studies in this manuscript tested whether the combination with oHSV and MEKi Trametinib can enhance oncolytic virus replication and oncolytic activity in BRAF-mutated or RAS-mutated tumor in vitro as well as the antitumor efficacy in vivo. Here, BRAF is linked to neoplasm.